Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? : Editorial to: "Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: A Multicenter Randomized Clinical Trial (AASER Study)" by M. Goicoechea et al

Affiliations

¹ Department of Medicine, Division of Nephrology, William Jennings Bryan Dorn VAMC, Columbia, SC, USA.
² Nephrology Section, Stratton VA Medical Center and Division of Nephrology, Department of Medicine, Albany Medical College, Albany, NY, USA.
³ Division of Cardiology, Albany Medical Center and Department of Medicine, Albany Medical College, 47 New Scotland Ave, Albany, NY, 12208, USA. sidhum@amc.edu.

Editorial

Roy O Mathew et al. Cardiovasc Drugs Ther. 2018 Jun.

. 2018 Jun;32(3):241-243.

doi: 10.1007/s10557-018-6803-0.

¹ Department of Medicine, Division of Nephrology, William Jennings Bryan Dorn VAMC, Columbia, SC, USA.
² Nephrology Section, Stratton VA Medical Center and Division of Nephrology, Department of Medicine, Albany Medical College, Albany, NY, USA.
³ Division of Cardiology, Albany Medical Center and Department of Medicine, Albany Medical College, 47 New Scotland Ave, Albany, NY, 12208, USA. sidhum@amc.edu.

No abstract available

Comment on

Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Luño J. Goicoechea M, et al. Cardiovasc Drugs Ther. 2018 Jun;32(3):255-263. doi: 10.1007/s10557-018-6802-1. Cardiovasc Drugs Ther. 2018. PMID: 29943364 Clinical Trial.